| 11.28 -0.09 (-0.79%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.03 | 1-year : | 16.39 |
| Resists | First : | 12.02 | Second : | 14.03 |
| Pivot price | 10.83  |
|||
| Supports | First : | 9.67 | Second : | 8.22 |
| MAs | MA(5) : | 11.18 |
MA(20) : | 10.32 |
| MA(100) : | 10.4  |
MA(250) : | 12.18 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 76 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 18.56 | Low : | 7.48 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BHVN ] has closed below upper band by 30.7%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.01 - 12.06 | 12.06 - 12.12 |
| Low: | 11.1 - 11.17 | 11.17 - 11.24 |
| Close: | 11.15 - 11.26 | 11.26 - 11.37 |
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Fri, 05 Jun 2026
Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%? - Yahoo Finance
Mon, 01 Jun 2026
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation - PR Newswire
Wed, 27 May 2026
Biohaven test drugs rapidly lower antibodies in Graves’ and IgA nephropathy - Stock Titan
Wed, 27 May 2026
Biohaven - Despite Today's Gains, I Remain Skeptical (NYSE:BHVN) - Seeking Alpha
Mon, 04 May 2026
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 151 (M) |
| Shares Float | 124 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 97.6 (%) |
| Shares Short | 24,100 (K) |
| Shares Short P.Month | 23,780 (K) |
| EPS | -5.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.86 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83.4 % |
| Return on Equity (ttm) | -333 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -594 (M) |
| Levered Free Cash Flow | -379 (M) |
| PE Ratio | -2.03 |
| PEG Ratio | 0 |
| Price to Book value | 13.11 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|